Lockheed Martin announced a $30 million prototype agreement with Rune Technologies to develop a data‑centric Next Generation Command and Control (NGC2) prototype for the U.S. Army’s 25th Infantry Division.
The deal integrates Rune’s TyrOS predictive logistics platform into the NGC2 effort, giving commanders real‑time visibility and automated decision support for supply chain operations in contested environments. The platform’s AI algorithms forecast material needs and optimize routing, enabling faster, more accurate logistics decisions for the 25th Infantry Division’s forward‑deployed units.
Lockheed’s role as team lead for the NGC2 prototype underscores its strategy of embedding commercial AI capabilities into defense systems. The $30 million contract adds a new revenue stream to Lockheed’s portfolio and is expected to be recognized in the current fiscal year, which ends in December. In 2024, Lockheed reported $71 billion in revenue, so the prototype award represents a modest but meaningful addition to its earnings base.
Lockheed’s vice‑president for Army modernization, Chandra Marshall, said the partnership “demonstrates Lockheed’s commitment to integrating advanced AI solutions that enhance operational effectiveness for warfighters.” Rune’s co‑founder and CEO, David Tuttle, added that the collaboration “leverages our predictive logistics technology to give commanders a decisive advantage in contested environments.”
The contract aligns with the Army’s broader NGC2 modernization effort, which seeks to replace legacy command and control systems with data‑centric, AI‑driven platforms. Analysts view the win as a positive signal of Lockheed’s expanding footprint in AI‑enabled defense solutions and a step toward capturing a larger share of the Army’s future modernization budget.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.